We use cookies to personalise content, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. If you want to change your cookie setting, please see the ‘how to reject cookies’ section of our Cookie Policy. Otherwise, if you agree to our use of cookies, please continue to use our website.

I Accept Cookies


When looking at the Digital Strength Index, pharmaceutical companies score on the low end of the spectrum overall. Even though Big Pharma could be considered digitally nascent, they just have a different interpretation of what digital transformation means. By making digital a priority, the system will become not only more efficient but more effective, allowing Big Pharma to focus on selling outcomes, not pills.



AbbVie is the high-growth ticker, aided by its relatively higher digital share among pharmaceuticals and recent Momentum.


Merck's digital strength assessment points to continued headwinds for future topline revenue growth.


Johnson & Johnson has the largest digital presence by far in terms of digital properties and overall consumer interactions across platforms.


Pfizer's digital strength has started to lose some Momentum but the company has a leg up on the peer group in driving interactions in Search and Social.


Johnson & Johnson and Pfizer lead in Magnitude due to their consumer-facing brands. However, the companies with consumer health divisions are starting to lose momentum, while smaller companies like AbbVie are catching up.


Big Pharma has been characteristically conservative in its adoption of new digital technologies. How can the pharma industry make a change and leverage digital innovation to avoid losing ground? Download our report to find out.